KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accumulated Expenses (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Accumulated Expenses for 6 consecutive years, with $70.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 14.22% year-over-year to $70.2 million, compared with a TTM value of $70.2 million through Dec 2025, down 14.22%, and an annual FY2025 reading of $70.2 million, down 14.22% over the prior year.
  • Accumulated Expenses was $70.2 million for Q4 2025 at Recursion Pharmaceuticals, up from $53.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $81.9 million in Q4 2024 and bottomed at $11.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $38.0 million, with a median of $32.9 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 208.37% in 2021, then fell 14.22% in 2025.
  • Year by year, Accumulated Expenses stood at $32.3 million in 2021, then increased by 1.77% to $32.9 million in 2022, then skyrocketed by 41.73% to $46.6 million in 2023, then surged by 75.56% to $81.9 million in 2024, then fell by 14.22% to $70.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for RXRX at $70.2 million in Q4 2025, $53.1 million in Q3 2025, and $64.3 million in Q2 2025.